HPV vaccination: facts versus fears
Numerous cancers have been attributed to the human papilloma virus (HPV), including cervical, vaginal, vulvar, penile, anorectal, and oropharyngeal. The incidence of HPV-related cancers in Ireland is 420 cases annually, resulting in 130 deaths. HPV is most frequently associated with cervical cancer; globally, over half a million women are diagnosed with this cancer each year. Serotypes HPV16 and HPV18 are associated with the highest cancer risk. The Irish prevention strategies include a national screening programme to detect cervical pre-cancer and cancerous lesions (namely cervical intraepithelial neoplasia; CIN) in women aged 25-60, as well as a national HPV vaccination programme. The HPV vaccine is recommended for young girls in the first year of second-level school, to provide protection against HPV prior to expected sexual exposure, thereby reducing the risk of HPV infection. There are a number of different HPV vaccines available; the two main types are Cervarix and Gardasil. Cervarix is a bivalent vaccine protecting against cancer-associated serotypes HPV16 and HPV18. Gardasil is a quadrivalent vaccine protecting against HPV16 and HPV18, as well as the genital warts-associated strains HPV6 and HPV11. The Gardasil vaccine was first introduced to Ireland’s national screening programme in 2011, but this has not been without contention.
CommentsThe original article is available at http://www.rcsismj.com/ Part of the RCSIsmj collection: https://doi.org/10.25419/rcsi.c.6786051.v1
Published CitationStaunton L. HPV vaccination: facts versus fears. RCSIsmj. 2018;11(1):73-76
- Undergraduate Research
PublisherRCSI University of Medicine and Health Sciences
- Published Version (Version of Record)